Astrocyte Pharmaceuticals Inc.


Astrocyte Pharmaceuticals is a new neuroscience drug development company with a novel small molecule drug for the treatment of stroke, traumatic brain injuries and concussions. The company has demonstrated significant neuroprotective efficacy in multiple mouse models, with acute treatment administered as late as 24 hours post injury. The company has over $2M in previous investment, NIH & DOD grants to advance their promising drug candidate.

Video Pitch

Management Team

Co-Founder and CEO

William Korinek

Previously VP of Worldwide R&D Business Operations at Pfizer; Managed annual investment business plans from all of Pfizer’s Research Units and functional Partner Lines and the setting of annual investment and budget targets; Championed and secured $24M in capital to overall Pfizer’s Project and Resource Planning, which he led and successfully implemented over 2011-2014; 5 year biopharma strategist as Engagement Manager at L.E.K. Consulting

VP of Pharmacokinetics and Pharmacodynamics

Theodore Liston

Formerly a Pfizer Vice-President in Pharmacokinetics, Dynamics and Metabolism (PDM) leading the operations of the largest PDM site, and guiding the work of >200 scientists; central roles in the successful discovery and clinical advancement of well over 100 diverse compounds targeting therapeutic endpoints in neuroscience and other TAs.

Co-Founder and Director

James Lechleiter

Professor of Cellular and Structural Biology at the University of Texas Health Science Center at San Antonio (UTHSCSA) Research focus on the molecular and cellular mechanisms of protection during acute brain injury, ischemic stress, and aging Sole inventor on US Patent #8,618,074 (licensed to Astrocyte) International leader in Ca+2 signaling; discovered intracellular spiral Ca+2 waves Over 50 peer-reviewed publications